We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Anavex Life Sciences Corporation | NASDAQ:AVXL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.47% | 3.44 | 3.38 | 3.84 | 3.48 | 3.37 | 3.40 | 949,972 | 00:48:08 |
“Our preclinical findings for ANAVEX 3-71 demonstrate its significant potential to enhance neuroprotection and cognition via concomitant activation of sigma-1 receptor and M1 muscarinic acetylcholine receptor (M1R), which could be a therapeutic advantage in treating Alzheimer’s and other related protein-aggregation diseases,” said study author Abraham Fisher, PhD. “Specifically, the study results reveal that ANAVEX 3-71 effects a strong reversal of synaptic loss in hippocampal neurons. At very low doses, it mitigates cognitive deficits and normalizes major pathological hallmarks in Alzheimer’s disease models indicating that ANAVEX 3-71 exerts a comprehensive disease-modifying effect. This data adds to the strong foundation of preclinical evidence to support the potential use of ANAVEX 3-71 in Alzheimer's disease and a wide array of other central nervous system diseases.”
“In addition to ANAVEX 2-73, which is currently the subject of an ongoing PART B longitudinal extension of the Phase 2a study, it appears that ANAVEX 3-71 could be a highly effective treatment for Alzheimer’s when compared with competing drugs, including donepezil (Aricept®), the current standard of care,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Based on the growing body of positive preclinical data, we look forward to continuing to advance ANAVEX 3-71 towards a potential first human clinical trial.”
The results of the preclinical study demonstrate that ANAVEX 3-71:
The paper, “AF710B, a Novel M1/ Sigma-1 Agonist with Therapeutic Efficacy in Animal Models of Alzheimer’s disease,” was published in Neurodegenerative Diseases. It was co-authored by A. Fisher, the inventor of ANAVEX 3-71, and I. Bezprozvanny, L. Wu, D. A. Ryskamp, N. Bar-Ner, N. Natan, R. Brandeis, H. Elkon, V. Nahum, E. Gershonov, F. M. LaFerla and R. Medeiros from the Israel Institute for Biological Research (Ness-Ziona, Israel), the University of Texas Southwestern Medical Center (Dallas, TX), St. Petersburg State Polytechnical University (St. Petersburg, Russia) and the University of California (Irvine, CA), respectively.
Dr. Abraham Fisher is a member of the Anavex Scientific Advisory Board.
About ANAVEX 3-71
ANAVEX 3-71, previously AF710B, is a promising preclinical drug candidate with a novel mechanism of action shown to enhance neuroprotection and cognition in Alzheimer’s disease. It is a CNS-penetrable mono-therapy that bridges treatment of both cognitive impairments with disease modifications. ANAVEX 3-71 is highly effective in very small doses against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also has beneficial effects on neuroinflammation and mitochondrial dysfunctions.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases and various types of cancer. Anavex’s lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept®), are currently in a Phase 2a clinical trial for Alzheimer’s disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in convulsive epileptic animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. Michael J. Fox Foundation (MJFF) for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media Relations Toll-free: 1-866-505-2895 Outside North America: +1 (416) 489-0092 Email: ir@anavex.com www.anavex.com
1 Year Anavex Life Sciences Chart |
1 Month Anavex Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions